What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α)”In the company’s words, NCT07033481 on ClinicalTrials.gov
- Main trialPhase 2
- “The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.”In the company’s words, NCT07033481 on ClinicalTrials.gov
- Other names
- VX-745
Other drugs for Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
- PembrolizumabMerck & Co. · Phase 3
- Cabergoline tabletsChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- IMU-838Immunic AG · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Sep 2026 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | |
| Phase 2Completed | 30 Jun 2019 | Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease | |
| Phase 2Completed | 30 Jun 2020 | Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies | |
| Phase 2Terminated | 15 Oct 2020 | Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease | |
| Phase 2Completed | 29 May 2025 | RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | |
| Phase 2Completed | 11 Mar 2026 | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | |
| Phase 2Completed | 23 Sep 2026 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026